Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
Rhea-AI Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its first quarter 2020 financial results on May 13, 2020, before the U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET, discussing these results and the latest corporate developments. The company is focused on treating genetically defined rare diseases, advancing its lead drug, losmapimod, to Phase 2 for facioscapulohumeral muscular dystrophy, while also working on FTX-6058 for sickle cell disease and beta-thalassemia.
Positive
- Advancing losmapimod to Phase 2 clinical development for FSHD.
- Extensive pre-clinical research completed for FTX-6058 targeting sickle cell disease and beta-thalassemia.
Negative
- None.
News Market Reaction – FULC
On the day this news was published, FULC declined 2.40%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2020 financial results will be released on Wednesday, May 13, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 8297069
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 8297069
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and has completed extensive pre-clinical research for FTX-6058 for the treatment of sickle cell disease and beta-thalassemia.
Please visit www.fulcrumtx.com.
Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com
FAQ
When will Fulcrum Therapeutics release its Q1 2020 financial results?
What time is the Fulcrum Therapeutics conference call?
What is Fulcrum Therapeutics' lead drug?
What diseases is Fulcrum Therapeutics targeting with FTX-6058?
